98%
921
2 minutes
20
Topic: The goal of this systematic review was to evaluate the measurement variability of distance visual acuity (VA) and refractive error (RE).
Clinical Relevance: Accurately measuring VA and RE is fundamental to eye care; however, no scientific consensus has been reached on the measurement variability. Scientific literature suggests limits of variability of ±0.15 logarithm of the minimum angle of resolution (logMAR) for VA and ±0.5 diopters (D) for RE. This lack of consensus on variability affects our clinical decision-making, regulations, and research.
Methods: This systematic review was performed in accordance with Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines and was registered at PROSPERO (ID CRD42024554663). We searched Medline, PubMed, and Embase databases. The Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool was then used to assess the risk of bias (RoB). We included studies of adults that directly compared distance VA or RE and reported the limits of agreement (LoA) and mean difference. An overall summarized mean is reported in LoA, and the certainty of evidence was assessed using Grading of Recommendation, Assessment, Development, and Evaluation.
Results: After applying the eligibility criteria, 12 studies reporting on VA and 6 studies reporting on RE were included. Six of the 18 studies (33%) scored a low RoB in at least 3 of 4 QUADAS-2 domains. Only 1 study had a low RoB in all four QUADAS-2 domains, whereas 13 of 18 studies had a high or unclear RoB in at least 3 of 4 QUADAS-2 domains. In 25 of 36 subgroups (69%), the LoA exceeded the suggested clinical accepted variability ranges for VA (±0.15 logMAR) or RE (±0.5 D). The overall summarized mean is ±0.20 logMAR (95% confidence interval [CI], 0.17-0.23) for VA and ±0.70 D (95% CI, 0.50-0.89) for RE. The Grading of Recommendation, Assessment, Development, and Evaluation certainty of evidence was very low.
Conclusions: This study demonstrates that distance VA and RE measurements have a high measurement variability in adults, exceeding the suggested limits of variability (VA: ±0.15 logMAR, RE: ±0.5 D). The evidence either fails to support the suggested limits of variability or is based on studies with methodological weaknesses, with a very low certainty of evidence. Methodological rigorous studies are therefore needed to accurately estimate the suggested limits of variability. For now, we propose using the overall summarized mean LoA obtained in our study as a provisional frame of reference (i.e., ±0.20 logMAR and ±0.70 D).
Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ophtha.2025.04.021 | DOI Listing |
J Intensive Care
September 2025
German Center for Vertigo and Balance Disorders, Ludwig-Maximilians-Universitat (LMU), University Hospital Grosshadern, Munich, Germany.
Background: Survivors of critical illness frequently face physical, cognitive and psychological impairments after intensive care. Sensorimotor impairments potentially have a negative impact on participation. However, comprehensive understanding of sensorimotor recovery and participation in survivors of critical illness is limited.
View Article and Find Full Text PDFNat Aging
September 2025
Department of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, Lørenskog, Norway.
Beyond their classical functions as redox cofactors, recent fundamental and clinical research has expanded our understanding of the diverse roles of nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP) in signaling pathways, epigenetic regulation and energy homeostasis. Moreover, NAD and NADP influence numerous diseases as well as the processes of aging, and are emerging as targets for clinical intervention. Here, we summarize safety, bioavailability and efficacy data from NAD-related clinical trials, focusing on aging and neurodegenerative diseases.
View Article and Find Full Text PDFJ Cancer Res Clin Oncol
September 2025
Department of Surgery, Mannheim School of Medicine, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Purpose: The study aims to compare the treatment recommendations generated by four leading large language models (LLMs) with those from 21 sarcoma centers' multidisciplinary tumor boards (MTBs) of the sarcoma ring trial in managing complex soft tissue sarcoma (STS) cases.
Methods: We simulated STS-MTBs using four LLMs-Llama 3.2-vison: 90b, Claude 3.
J Assist Reprod Genet
September 2025
Bahçeci Fulya IVF Center, Infertility Clinic, Istanbul, Turkey.
Purpose: To assess the intra-individual variability of serum progesterone (P) levels on embryo transfer (ET) day, when the same dose of intramuscular progesterone (IM-P) was used in two consecutive hormone replacement therapy (HRT) frozen embryo transfer (FET) cycles.
Methods: A total of 75 patients undergoing two consecutive HRT-FET cycles in one year performed at Bahceci Ankara IVF Center between November 2019 and February 2022 were retrospectively analyzed. Serum P levels were measured at the 117th-119th hours of support by a single laboratory.
Ann Hematol
September 2025
Hematology and Transplant Center, University Hospital"San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy.
Functional high risk multiple myeloma (FHRMM) remains a challenging entity with poor outcomes and limited survival, and there is no international consensus on optimal second-line therapeutic strategies in relapsed/refractory patients. In this multicenter real-world retrospective study, we investigated clinical characteristics and outcomes of a total of 62 FHRMM patients previously treated with a first-line daratumumab-based quadruplet regimen or who relapsed within 12 months after frontline autologous stem cell transplantation (ASCT). In our cohort, the overall response rate was 61%, with 42% of patients achieving a very good partial response (VGPR) or better.
View Article and Find Full Text PDF